Patrizia Mecocci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7530005/publications.pdf

Version: 2024-02-01

4645 2975 35,462 368 93 170 citations h-index g-index papers 391 391 391 40523 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Alzheimer's disease: clinical trials and drug development. Lancet Neurology, The, 2010, 9, 702-716.	10.2	1,033
4	Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Annals of Neurology, 1994, 36, 747-751.	5. 3	992
5	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
6	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
7	Oxidative damage to mitochondrial DNA shows marked ageâ€dependent increases in human brain. Annals of Neurology, 1993, 34, 609-616.	5.3	713
8	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
9	Oxidative stress in brain aging, neurodegenerative and vascular diseases: An overview. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 827, 65-75.	2.3	556
10	Clinical trials and lateâ€stage drug development for <scp>A</scp> zheimer's disease: an appraisal from 1984 to 2014. Journal of Internal Medicine, 2014, 275, 251-283.	6.0	540
11	Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiology of Aging, 2003, 24, 915-919.	3.1	530
12	Marked Decrease in Plasma Antioxidants in Aged Osteoporotic Women: Results of a Cross-Sectional Study. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1523-1527.	3.6	472
13	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	6.2	419
14	Age-dependent increases in oxidative damage to DNA, lipids, and proteins in human skeletal muscle. Free Radical Biology and Medicine, 1999, 26, 303-308.	2.9	393
15	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
16	Potential markers of oxidative stress in stroke. Free Radical Biology and Medicine, 2005, 39, 841-852.	2.9	354
17	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
18	Validation of the Five-Item Geriatric Depression Scale in Elderly Subjects in Three Different Settings. Journal of the American Geriatrics Society, 2003, 51, 694-698.	2.6	334

#	Article	IF	CITATIONS
19	Neuropsychiatric Syndromes in Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 24, 457-463.	1.5	305
20	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
21	Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. Journal of Neuroscience, 1995, 15, 8419-8429.	3.6	280
22	Plasma antioxidants and longevity: a study on healthy centenarians. Free Radical Biology and Medicine, 2000, 28, 1243-1248.	2.9	256
23	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	3.1	256
24	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
25	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2018, 14, 280-292.	0.8	246
26	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. NeuroImage: Clinical, 2014, 6, 115-125.	2.7	233
27	Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 631-638.	3.8	217
28	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
29	Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer Disease. Archives of Neurology, 2002, 59, 794.	4.5	212
30	Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Research Reviews, 2009, 8, 285-305.	10.9	211
31	"Delirium Day― a nationwide point prevalence study of delirium in older hospitalized patients using an easy standardized diagnostic tool. BMC Medicine, 2016, 14, 106.	5.5	204
32	Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. Nature Neuroscience, 2016, 19, 420-431.	14.8	204
33	Antioxidant Profile and Early Outcome in Stroke Patients. Stroke, 2000, 31, 2295-2300.	2.0	203
34	Mild Cognitive Impairment: A Systematic Review. Journal of Alzheimer's Disease, 2007, 12, 23-35.	2.6	202
35	Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Molecular and Chemical Neuropathology, 1997, 31, 53-64.	1.0	200
36	AddNeuroMedâ€"The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	3.8	193

3

#	Article	IF	CITATIONS
37	Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neuroscience Letters, 1999, 272, 53-56.	2.1	192
38	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
39	Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neurolmage, 2011, 56, 212-219.	4.2	190
40	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
41	A Long Journey into Aging, Brain Aging, and Alzheimer's Disease Following the Oxidative Stress Tracks. Journal of Alzheimer's Disease, 2018, 62, 1319-1335.	2.6	181
42	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.8	180
43	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
44	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
45	An ontology-based personalization of health-care knowledge to support clinical decisions for chronically ill patients. Journal of Biomedical Informatics, 2012, 45, 429-446.	4.3	170
46	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
47	Management of Glaucoma: Focus on Pharmacological Therapy. Drugs and Aging, 2005, 22, 1-21.	2.7	166
48	Oxidative damage to DNA in lymphocytes from AD patients. Neurology, 1998, 51, 1014-1017.	1.1	165
49	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
50	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
51	Predictors of high level of burden and distress in caregivers of demented patients: results of an Italian multicenter study. International Journal of Geriatric Psychiatry, 2005, 20, 168-174.	2.7	151
52	Cognitive impairment: a key feature of congestive heart failure in the elderly. Journal of Neurology, 2003, 250, 1456-1463.	3.6	149
53	Education increases reserve against Alzheimer's disease—evidence from structural MRI analysis. Neuroradiology, 2012, 54, 929-938.	2.2	148
54	High Plasma Levels of Vitamin E Forms and Reduced Alzheimer's Disease Risk in Advanced Age. Journal of Alzheimer's Disease, 2010, 20, 1029-1037.	2.6	144

#	Article	IF	CITATIONS
55	Association of blood lipids with Alzheimer's disease: AÂcomprehensiveÂlipidomics analysis. Alzheimer's and Dementia, 2017, 13, 140-151.	0.8	144
56	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.8	143
57	Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radical Biology and Medicine, 2000, 29, 1252-1259.	2.9	141
58	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	2.6	141
59	Mild Cognitive Impairment: Epidemiology and Dementia Risk in an Elderly Italian Population. Journal of the American Geriatrics Society, 2008, 56, 51-58.	2.6	138
60	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	2.7	137
61	Age and sex influence on oxidative damage and functional status in human skeletal muscle. Journal of Muscle Research and Cell Motility, 2001, 22, 345-351.	2.0	136
62	Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiology of Aging, 2012, 33, 2282-2290.	3.1	134
63	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
64	Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Molecular Psychiatry, 2011, 16, 1130-1138.	7.9	133
65	Mitochondrial genes are altered in blood early in Alzheimer's disease. Neurobiology of Aging, 2017, 53, 36-47.	3.1	132
66	1H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging. NeuroReport, 2001, 12, 2315-2317.	1.2	131
67	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neurolmage, 2011, 54, 1178-1187.	4.2	128
68	The AddNeuroMed framework for multiâ€centre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	2.7	127
69	Association of the Estrogen Receptor \hat{l}_{\pm} Gene Polymorphisms with Sporadic Alzheimer's Disease. Biochemical and Biophysical Research Communications, 1999, 265, 335-338.	2.1	122
70	High Fruit and Vegetable Intake is Positively Correlated with Antioxidant Status and Cognitive Performance in Healthy Subjects. Journal of Alzheimer's Disease, 2009, 17, 921-927.	2.6	122
71	Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer's Disease. PLoS ONE, 2013, 8, e64971.	2.5	122
72	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	3.8	121

#	Article	IF	CITATIONS
73	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	4.2	121
74	Elderly Patients With Cognitive Impairment Have a High Risk for Functional Decline During Hospitalization: The GIFA Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1576-1580.	3.6	119
75	Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. Journal of Alzheimer's Disease, 2002, 4, 517-522.	2.6	115
76	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115
77	Plasma Antioxidant Status, Immunoglobulin G Oxidation and Lipid Peroxidation in Demented Patients: Relevance to Alzheimer Disease and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2004, 18, 265-270.	1.5	110
78	The Caregiver Burden Inventory in evaluating the burden of caregivers of elderly demented patients: results from a multicenter study. Aging Clinical and Experimental Research, 2005, 17, 46-53.	2.9	110
79	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	2.9	110
80	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	3.1	110
81	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	2.5	106
82	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	3.6	106
83	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 755-766.	2.6	105
84	Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Translational Psychiatry, 2015, 5, e494-e494.	4.8	105
85	Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1375-1385.	3.1	104
86	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	2.5	103
87	Effect of a <i>CYP2D6</i> polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73, 761-767.	1.1	102
88	Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy. Neurobiology of Aging, 2006, 27, 926-932.	3.1	101
89	Increased Protein and Lipid Oxidative Damage in Mitochondria Isolated from Lymphocytes from Patients with Alzheimer's Disease: Insights into the Role of Oxidative Stress in Alzheimer's Disease and Initial Investigations into a Potential Biomarker for this Dementing Disorder. Journal of Alzheimer's Disease. 2011. 24. 77-84.	2.6	100
90	Cognitive Enhancement Therapy for Alzheimerʽs Disease. Drugs, 1997, 53, 752-768.	10.9	99

#	Article	IF	Citations
91	Plasma Carotenoid and Malondialdehyde Levels in Ischemic Stroke Patients: Relationship to Early Outcome. Free Radical Research, 2002, 36, 265-268.	3.3	99
92	Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Experimental Gerontology, 2013, 48, 1428-1435.	2.8	99
93	Nutraceuticals in cognitive impairment and Alzheimer $ ilde{A}$ ¢ \hat{a} , $\neg \hat{a}$,,¢s disease. Frontiers in Pharmacology, 2014, 5, 147.	3.5	99
94	From cellular senescence to Alzheimer's disease: The role of telomere shortening. Ageing Research Reviews, 2015, 22, 1-8.	10.9	99
95	Cigarette smoking cessation increases plasma levels of several antioxidant micronutrients and improves resistance towards oxidative challenge. British Journal of Nutrition, 2003, 90, 147-150.	2.3	98
96	Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Research - Neuroimaging, 2013, 212, 89-98.	1.8	98
97	Plasma levels of lipophilic antioxidants in very old patients with Type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2000, 16, 15-19.	4.0	97
98	Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radical Biology and Medicine, 1998, 25, 561-567.	2.9	95
99	Cognitive Impairment Is the Major Risk Factor for Development of Geriatric Syndromes during Hospitalization: Results from the GIFA Study. Dementia and Geriatric Cognitive Disorders, 2005, 20, 262-269.	1.5	94
100	Identification of <i>cis-</i> regulatory variation influencing protein abundance levels in human plasma. Human Molecular Genetics, 2012, 21, 3719-3726.	2.9	94
101	Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGAI project. International Journal of Geriatric Psychiatry, 2008, 23, 523-530.	2.7	92
102	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	2.6	91
103	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> zheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	6.0	91
104	Diabetes drugs in the fight against Alzheimer's disease. Ageing Research Reviews, 2019, 54, 100936.	10.9	91
105	Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity. Free Radical Biology and Medicine, 2002, 32, 148-152.	2.9	90
106	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	11.6	90
107	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
108	Plasma Vitamin C Levels Are Decreased and Correlated With Brain Damage in Patients With Intracranial Hemorrhage or Head Trauma. Stroke, 2001, 32, 898-902.	2.0	88

#	Article	IF	Citations
109	Interaction Between Bone and Muscle in Older Persons with Mobility Limitations. Current Pharmaceutical Design, 2014, 20, 3178-3197.	1.9	88
110	Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. Journal of Cardiac Failure, 2004, 10, 334-338.	1.7	86
111	Metabolic Syndrome and Risk of Dementia in Older Adults. Journal of the American Geriatrics Society, 2010, 58, 487-492.	2.6	86
112	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
113	Vitamin E levels, cognitive impairment and dementia in older persons: the InCHIANTI study. Neurobiology of Aging, 2005, 26, 987-994.	3.1	84
114	Apathy and cortical atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2011, 26, 741-748.	2.7	84
115	The orthogeriatric comanagement improves clinical outcomes of hip fracture in older adults. Osteoporosis International, 2019, 30, 907-916.	3.1	83
116	Effect of APOE $\hat{l}\mu 4$ Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
117	Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry, 2013, 18, 781-787.	7.9	81
118	Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Experimental Gerontology, 2008, 43, 445-451.	2.8	77
119	Insight, cognition and quality of life in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 331-336.	1.9	77
120	A Review of the Major Vascular Risk Factors Related to Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 32, 521-530.	2.6	77
121	Physical Activity and Oxidative Stress During Aging. International Journal of Sports Medicine, 2000, 21, 154-157.	1.7	76
122	Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids, 2007, 32, 553-559.	2.7	75
123	Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. Acta Psychiatrica Scandinavica, 2008, 117, 455-464.	4.5	75
124	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
125	Tau Protein in Cerebrospinal Fluid. Alzheimer Disease and Associated Disorders, 1998, 12, 211-214.	1.3	74
126	Mitochondrial DNA 4977 bp deletion and OH 8 dG levels correlate in the brain of aged subjects but not Alzheimer's disease patients. FASEB Journal, 1999, 13, 1083-1088.	0.5	74

#	Article	IF	CITATIONS
127	Fatigue: Relevance and implications in the aging population. Experimental Gerontology, 2015, 70, 78-83.	2.8	73
128	Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. European Journal of Clinical Pharmacology, 1992, 42, 89-93.	1.9	72
129	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
130	Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsâ€"The AddNeuroMed study. Neurobiology of Aging, 2011, 32, 1198-1206.	3.1	69
131	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	1.8	69
132	Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurologica Scandinavica, 1991, 84, 210-213.	2.1	68
133	Dietary habits are major determinants of the plasma antioxidant status in healthy elderly subjects. British Journal of Nutrition, 2005, 94, 639-642.	2.3	67
134	Classification and prediction of clinical diagnosis of Alzheimer's disease based on <scp>MRI</scp> and plasma measures of αâ€Î³â€tocotrienols and γâ€tocopherol. Journal of Internal Medicine, 2013, 273, 602-621.	6.0	67
135	Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: postâ€hoc analyses of ADASâ€cog and SIB total and singleâ€item scores from six randomized, doubleâ€blind, placeboâ€controlled studies. International Journal of Geriatric Psychiatry, 2009, 24, 532-538.	2.7	65
136	Oxidative stress in mild cognitive impairment and Alzheimer disease: A continuum. Journal of Alzheimer's Disease, 2004, 6, 159-163.	2.6	64
137	Short-term and long-term vitamin C supplementation in humans dose-dependently increases the resistance of plasma to ex vivo lipid peroxidation. Archives of Biochemistry and Biophysics, 2004, 423, 109-115.	3.0	63
138	Serum anti-GFAP and anti-S100 autoantibodies in brain aging, Alzheimer's disease and vascular dementia. Journal of Neuroimmunology, 1995, 57, 165-170.	2.3	62
139	Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease. Pharmacogenetics and Genomics, 2011, 21, 225-230.	1.5	62
140	Influence of age, disease onset and <i>ApoE4</i> on visual medial temporal lobe atrophy cutâ€offs. Journal of Internal Medicine, 2014, 275, 317-330.	6.0	60
141	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 20.	6.2	60
142	Decreased expression and increased oxidation of plasma haptoglobin in Alzheimer disease: Insights from redox proteomics. Free Radical Biology and Medicine, 2012, 53, 1868-1876.	2.9	59
143	Altered mitochondrial membrane fluidity in AD brain. Neuroscience Letters, 1996, 207, 129-132.	2.1	57
144	Body mass index, lifestyles, physical performance and cognitive decline: The "Treviso Longeva (Trelong)―study. Journal of Nutrition, Health and Aging, 2013, 17, 378-384.	3.3	57

#	Article	IF	Citations
145	Lymphocyte mitochondria: toward identification of peripheral biomarkers in the progression of Alzheimer disease. Free Radical Biology and Medicine, 2013, 65, 595-606.	2.9	56
146	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	3.1	56
147	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
148	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
149	Decreased dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) concentrations in plasma of Alzheimer's disease (AD) patients. Archives of Gerontology and Geriatrics, 2010, 51, e16-e18.	3.0	55
150	Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. American Journal of Clinical Nutrition, 2008, 87, 1306-1313.	4.7	54
151	Axonal injury within language network in primary progressive aphasia. Annals of Neurology, 2003, 53, 242-247.	5.3	53
152	An MRIâ€based index to measure the severity of Alzheimer's diseaseâ€like structural pattern in subjects with mild cognitive impairment. Journal of Internal Medicine, 2013, 273, 396-409.	6.0	53
153	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
154	Pooled Analyses on Cognitive Effects of Memantine in Patients with Moderate to Severe Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 193-199.	2.6	50
155	Vitamin E family: Role in the pathogenesis and treatment of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 182-191.	3.7	49
156	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
157	Development of a Short Form of the Severe Impairment Battery. American Journal of Geriatric Psychiatry, 2005, 13, 999-1005.	1.2	48
158	Validation Study of the Italian Addenbrooke's Cognitive Examination Revised in a Young-Old and Old-Old Population. Dementia and Geriatric Cognitive Disorders, 2011, 32, 301-307.	1.5	48
159	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
160	Physical activity and inflammation: effects on grayâ€matter volume and cognitive decline in aging. Human Brain Mapping, 2016, 37, 3462-3473.	3.6	48
161	Antioxidants for the treatment of mild cognitive impairment. Neurological Research, 2004, 26, 598-602.	1.3	47
162	Cognitive Performance in Elderly Patients Undergoing Carotid Endarterectomy or Carotid Artery Stenting: A Twelve-Month Follow-Up Study. Cerebrovascular Diseases, 2010, 30, 244-251.	1.7	47

#	Article	IF	Citations
163	Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression. Journal of Alzheimer's Disease, 2011, 26, 395-405.	2.6	47
164	Nutrition and lifestyle in healthy aging: the telomerase challenge. Aging, 2016, 8, 12-15.	3.1	46
165	Polypharmacy in older people: lessons from 10Âyears of experience with the REPOSIÂregister. Internal and Emergency Medicine, 2018, 13, 1191-1200.	2.0	45
166	Predicting Progression of Alzheimer's Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	2.5	44
167	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	1.8	44
168	Antioxidant enzyme activities in healthy old subjects: influence of age, gender and zinc status. Biogerontology, 2006, 7, 391-398.	3.9	43
169	HO-1/BVR-A System Analysis in Plasma from Probable Alzheimer's Disease and Mild Cognitive Impairment Subjects: A Potential Biochemical Marker for the Prediction of the Disease. Journal of Alzheimer's Disease, 2012, 32, 277-289.	2.6	43
170	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	2.6	43
171	Lymphocytic Mitochondrial Aconitase Activity is Reduced in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 44, 649-660.	2.6	42
172	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. Scientific Reports, 2018, 8, 11592.	3.3	41
173	APOE & Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	1.5	40
174	CERAD Neuropsychological Battery Total Score in Multinational Mild Cognitive Impairment and Control Populations: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2011, 22, 1089-1097.	2.6	40
175	Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	4.8	39
176	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	4.5	39
177	Elevated Lipid Peroxidation Biomarkers and Low Antioxidant Status in Atherosclerotic Patients with Increased Carotid or Iliofemoral Intima Media Thickness. Journal of Investigative Medicine, 2007, 55, 163-167.	1.6	38
178	Vitamin E Biotransformation in Humans. Vitamins and Hormones, 2007, 76, 263-280.	1.7	38
179	Clinical Features Associated with Delirium Motor Subtypes in Older Inpatients: Results of a Multicenter Study. American Journal of Geriatric Psychiatry, 2017, 25, 1064-1071.	1.2	38
180	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. NeuroImage: Clinical, 2017, 15, 613-624.	2.7	38

#	Article	IF	CITATIONS
181	Development of a Short Form of the Severe Impairment Battery. American Journal of Geriatric Psychiatry, 2005, 13, 999-1005.	1.2	38
182	Early post-surgical cognitive dysfunction is a risk factor for mortality among hip fracture hospitalized older persons. Osteoporosis International, 2017, 28, 667-675.	3.1	37
183	Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. International Psychogeriatrics, 2012, 24, 99-107.	1.0	36
184	A Multi-Cohort Study of ApoE É>4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	2.6	36
185	Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clinical Biochemistry, 2010, 43, 267-271.	1.9	35
186	Hypertension and Cognitive Function in the Elderly. Disease-a-Month, 2010, 56, 106-147.	1.1	35
187	Lysosomal \hat{l}^2 -Galactosidase and \hat{l}^2 -Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus. Journal of Alzheimer's Disease, 2011, 24, 785-797.	2.6	35
188	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. Journal of Alzheimer's Disease, 2014, 39, 679-690.	2.6	35
189	Fracture prevention service to bridge the osteoporosis care gap. Clinical Interventions in Aging, 2015, 10, 1035.	2.9	35
190	The clock drawing test as a screening tool in mild cognitive impairment and very mild dementia: a new brief method of scoring and normative data in the elderly. Neurological Sciences, 2016, 37, 867-873.	1.9	35
191	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	2.7	35
192	Proton Magnetic Resonance Spectroscopy Reveals Similar White Matter Biochemical Changes in Patients with Chronic Hypertension and Early Alzheimer's Disease. Journal of the American Geriatrics Society, 2002, 50, 1707-1710.	2.6	34
193	Hypertension and Cognitive Function in the Elderly. American Journal of Therapeutics, 2007, 14, 533-554.	0.9	34
194	Beta-carotene, telomerase activity and Alzheimer's disease in old age subjects. European Journal of Nutrition, 2020, 59, 119-126.	3.9	34
195	Association between apolipoprotein E e4 allele and apathy in probable Alzheimer's disease Acta Psychiatrica Scandinavica, 2006, 113, 59-63.	4.5	33
196	Plasma Levels of Complement 4a Protein are Increased in Alzheimer's Disease. Alzheimer Disease and Associated Disorders, 2012, 26, 329-334.	1.3	33
197	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	7.9	33
198	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33

#	Article	IF	CITATIONS
199	Congestive heart failure and Alzheimer's disease. Neurological Research, 2006, 28, 588-594.	1.3	32
200	Transethnic meta-analysis of rare coding variants in PLCG2, ABI3, and TREM2 supports their general contribution to Alzheimer's disease. Translational Psychiatry, 2019, 9, 55.	4.8	32
201	Depression in the elderly: new concepts and therapeutic approaches. Aging Clinical and Experimental Research, 2004, 16, 176-189.	2.9	31
202	Visuospatial Planning and Problem Solving in Alzheimer's Disease Patients: A Study with the Tower of London Test. Dementia and Geriatric Cognitive Disorders, 2007, 24, 424-428.	1.5	31
203	Vascular Risk Factors in Mild Cognitive Impairment Subtypes. Dementia and Geriatric Cognitive Disorders, 2007, 24, 448-456.	1.5	31
204	Blood homocysteine and risk of depression in the elderly. Archives of Gerontology and Geriatrics, 2010, 51, 21-25.	3.0	31
205	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	2.6	31
206	Cachexia and advanced dementia. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 263-277.	7.3	31
207	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
208	Rapidly Progressive Aphasic Dementia with Motor Neuron Disease: A Distinctive Clinical Entity. Dementia and Geriatric Cognitive Disorders, 2004, 17, 21-28.	1.5	30
209	Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 764-775.	6.4	30
210	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	2.6	30
211	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	3.3	30
212	COVID-19: A Geriatric Emergency. Geriatrics (Switzerland), 2020, 5, 24.	1.7	30
213	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. Molecular Psychiatry, 2021, 26, 5797-5811.	7.9	30
214	Immunohistochemical detection of the lipid peroxidation product 4-hydroxynonenal after experimental brain injury in the rat. Neuroscience Letters, 1999, 272, 57-61.	2.1	29
215	Interaction of CTSD and A2M polymorphisms in the risk for Alzheimer's disease. Journal of the Neurological Sciences, 2006, 247, 187-191.	0.6	29
216	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	3.4	29

#	Article	IF	Citations
217	Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegenerative Diseases, 2016, 16, 77-86.	1.4	29
218	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	3.4	29
219	Senotherapeutics: Targeting senescent cells for the main age-related diseases. Mechanisms of Ageing and Development, 2021, 197, 111526.	4.6	29
220	Heart disease and vascular risk factors in the cognitively impaired elderly: Implications for Alzheimer's dementia. Aging Clinical and Experimental Research, 2001, 13, 231-239.	2.9	28
221	Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia. International Journal of Molecular Sciences, 2017, 18, 2672.	4.1	28
222	Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. Journal of Translational Medicine, 2012, 10, 217.	4.4	26
223	Vitamin E and Alzheimer's disease: the mediating role of cellular aging. Aging Clinical and Experimental Research, 2020, 32, 459-464.	2.9	26
224	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	12.8	26
225	Use of Artificial Networks in Clinical Trials: A Pilot Study to Predict Responsiveness to Donepezil in Alzheimer's Disease. Journal of the American Geriatrics Society, 2002, 50, 1857-1860.	2.6	24
226	Functional Disability in Early Alzheimer's Disease – A Validation Study of the Italian Version of the Disability Assessment for Dementia Scale. Dementia and Geriatric Cognitive Disorders, 2008, 25, 186-194.	1.5	24
227	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24
228	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. Alzheimer's and Dementia, 2022, 18, 29-42.	0.8	24
229	Antihistone and anti-dsDNA autoantibodies in Alzheimer's disease and vascular dementia. Biological Psychiatry, 1993, 34, 380-385.	1.3	23
230	Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizophrenia. Peptides, 2001, 22, 67-72.	2.4	23
231	High Vitamin E Plasma Levels and Low Low-Density Lipoprotein Oxidation Are Associated with the Absence of Atherosclerosis in Octogenarians. Journal of the American Geriatrics Society, 2001, 49, 651-654.	2.6	23
232	Effects of vitamin C and aspirin in ischemic strokeâ€related lipid peroxidation: Results of the AVASAS (Aspirin Versus Ascorbic acid plus Aspirin in Stroke) Study. BioFactors, 2005, 24, 265-274.	5.4	23
233	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	6.2	23
234	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	4.5	23

#	Article	IF	CITATIONS
235	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	1.4	23
236	Prevalence of Aging-Associated Cognitive Decline in an Italian elderly population: results from cross-sectional phase of Italian PRoject on Epidemiology of Alzheimer's disease (IPREA). Aging Clinical and Experimental Research, 2010, 22, 440-449.	2.9	22
237	A Validation Study of Vascular Cognitive Impairment Genetics Meta-Analysis Findings in an Independent Collaborative Cohort. Journal of Alzheimer's Disease, 2016, 53, 981-989.	2.6	22
238	Healthy brain ageing and cognition: Nutritional factors. European Geriatric Medicine, 2016, 7, 77-85.	2.8	22
239	Different antioxidant profiles in Italian centenarians: the Sardinian peculiarity. European Journal of Clinical Nutrition, 2007, 61, 922-924.	2.9	21
240	Association of MT1A haplotype with cardiovascular disease and antioxidant enzyme defense in elderly Greek population: comparison with an Italian cohort. Journal of Nutritional Biochemistry, 2010, 21, 1008-1014.	4.2	21
241	Anticholinergic burden and functional status in older people with cognitive impairment: Results from the ReGAl project. Journal of Nutrition, Health and Aging, 2017, 21, 389-396.	3.3	21
242	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	3.4	21
243	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. PLoS ONE, 2011, 6, e17298.	2.5	21
244	Modeling the dynamics of energy imbalance: The free radical theory of aging and frailty revisited. Free Radical Biology and Medicine, 2022, 181, 235-240.	2.9	21
245	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20
246	Does the 15-item Geriatric Depression Scale function differently in old people with different levels of cognitive functioning?. Journal of Affective Disorders, 2018, 227, 471-476.	4.1	20
247	Glutathione Serum Levels and Rate of Multimorbidity Development in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1089-1094.	3.6	20
248	Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 4333-4344.	4.0	19
249	Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 51-59.	1.3	19
250	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	2.4	19
251	Psychotic Symptoms in Alzheimer's Disease and 5-HTTLPR Polymorphism of the Serotonin Transporter Gene: Evidence for an Association. Journal of Alzheimer's Disease, 2009, 16, 173-180.	2.6	18
252	Emotional and Psychological Distress of Persons Involved in the Care of Patients with Alzheimer Disease Predicts Falls and Fractures in Their Care Recipients. Dementia and Geriatric Cognitive Disorders, 2010, 30, 33-38.	1.5	18

#	Article	IF	Citations
253	Neuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene. International Journal of Alzheimer's Disease, 2011, 2011, 1-14.	2.0	18
254	The local reliability of the 15-item version of the Geriatric Depression Scale: An item response theory (IRT) study. Journal of Psychosomatic Research, 2017, 96, 84-88.	2.6	18
255	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). Neurolmage: Clinical, 2019, 23, 101846.	2.7	18
256	Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain, Behavior, and Immunity, 1992, 6, 286-292.	4.1	17
257	Is multi-infarct dementia representative of vascular dementias? A retrospective study. Acta Neurologica Scandinavica, 1990, 81, 484-487.	2.1	17
258	Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?. Journal of Alzheimer's Disease, 2018, 64, S397-S404.	2.6	17
259	Association of Peripheral Insulin Resistance and Other Markers of Type 2 Diabetes Mellitus with Brain Amyloid Deposition in Healthy Individuals at Risk of Dementia. Journal of Alzheimer's Disease, 2020, 76, 1243-1248.	2.6	17
260	Uric acid and late-onset Alzheimer's disease: results from the ReGAl 2.0 project. Aging Clinical and Experimental Research, 2021, 33, 361-366.	2.9	17
261	Prevalence and Correlates of Behavioral Disorders in Old Age Subjects with Cognitive Impairment: Results from the ReGAl Project. Journal of Alzheimer's Disease, 2017, 60, 1275-1283.	2.6	17
262	Pathogenetic mechanisms in vascular dementia. International Journal of Clinical and Laboratory Research, 1994, 24, 15-22.	1.0	16
263	Influence of ± 1245 A/G MT1A polymorphism on advanced glycation end-products (AGEs) in elderly: effect of zinc supplementation. Genes and Nutrition, 2014, 9, 426.	2.5	16
264	Effects of Weekly Supplementation of Cholecalciferol and Calcifediol Among the Oldest-Old People: Findings From a Randomized Pragmatic Clinical Trial. Nutrients, 2019, 11, 2778.	4.1	16
265	AUTOANTIBODIES AGAINST OXIDIZED LOWâ€DENSITY LIPOPROTEINS IN OLDER STROKE PATIENTS. Journal of the American Geriatrics Society, 1997, 45, 125-125.	2.6	15
266	Genetic Factors Associated With the Absence of Atherosclerosis in Octogenarians. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2002, 57, M611-M615.	3.6	15
267	Association of increased carotid intima–media thickness and lower plasma levels of vitamin C and vitamin E in old age subjects: implications for Alzheimer's disease. Journal of Neural Transmission, 2015, 122, 523-530.	2.8	15
268	Serum alkaline phosphatase is elevated and inversely correlated with cognitive functions in subjective cognitive decline: results from the ReGAl 2.0 project. Aging Clinical and Experimental Research, 2021, 33, 603-609.	2.9	15
269	The impact of aging in dementia: It is time to refocus attention on the main risk factor of dementia. Ageing Research Reviews, 2021, 65, 101210.	10.9	15
270	Platelet MAO-B activity and vitamin B12 in old age dementias. Molecular and Chemical Neuropathology, 1992, 16, 23-32.	1.0	14

#	Article	IF	CITATIONS
271	CSF monoamine metabolites in old age dementias. Molecular and Chemical Neuropathology, 1992, 16, 143-157.	1.0	14
272	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease1. Journal of Alzheimer's Disease, 2019, 68, 383-394.	2.6	14
273	Hypovitaminosis D: A Disease Marker in Hospitalized Very Old Persons at Risk of Malnutrition. Nutrients, 2019, 11, 128.	4.1	14
274	MicroRNAs Modulate the Pathogenesis of Alzheimer's Disease: An In Silico Analysis in the Human Brain. Genes, 2020, 11, 983.	2.4	14
275	Peripheral non-enzymatic antioxidant changes with human aging: a selective status report. Biogerontology, 2001, 2, 99-104.	3.9	13
276	Cathepsin D Polymorphism in Italian Elderly Subjects with Sporadic Late-Onset Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2003, 16, 151-155.	1.5	13
277	Normative data for the ACE-R in an Italian population sample. Neurological Sciences, 2015, 36, 2185-2190.	1.9	13
278	Cognitive Decline and Alzheimer's Disease in Old Age: A Sex-Specific Cytokinome Signature. Journal of Alzheimer's Disease, 2019, 72, 911-918.	2.6	13
279	Effectiveness of a high-throughput genetic analysis in the identification of responders/non-responders to CYP2D6-metabolized drugs. Clinical Laboratory, 2011, 57, 887-93.	0.5	13
280	Is the 15-item Geriatric Depression Scale a Fair Screening Tool? A Differential Item Functioning Analysis Across Gender and Age. Psychological Reports, 2018, 121, 1167-1182.	1.7	12
281	Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD. Alzheimer's Research and Therapy, 2022, 14, 37.	6.2	12
282	Oxidative stress and dementia: new perspectives in AD pathogenesis. Aging Clinical and Experimental Research, 1997, 9, 51-52.	2.9	11
283	Biomarkers for Early Diagnosis ofÂAlzheimer's Disease in the Oldest Old: Yes or No?. Journal of Alzheimer's Disease, 2017, 58, 323-335.	2.6	11
284	Short-Term Response is not Predictive ofÂLong-Term Response toÂAcetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A"Real World―Study. Journal of Alzheimer's Disease, 2017, 56, 239-248.	2.6	11
285	Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia. Journal of the American Medical Directors Association, 2020, 21, 486-492.e7.	2.5	11
286	The Importance of Cellular Senescence in Frailty and Cardiovascular Diseases. Advances in Experimental Medicine and Biology, 2020, 1216, 79-86.	1.6	11
287	THE TREVISO DEMENTIA (TREDEM) STUDY: A BIOMEDICAL, NEURORADIOLOGICAL, NEUROPSYCHOLOGICAL AND SOCIAL INVESTIGATION OF DEMENTIA IN NORTH-EASTERN ITALY. Journal of Frailty & Dementia (1), 12012, 1, 1-7.	1.3	11
288	Neuropsychological Results of Long-Term Therapy with Oxiracetam in Patients with Dementia of Alzheimer Type and Multi-Infarct Dementia in Comparison with a Control Group. Neuropsychobiology, 1989, 22, 97-100.	1.9	10

#	Article	IF	CITATIONS
289	Neuropsychological assessment of the severely impaired elderly patient: Validation of the Italian short version of the Severe Impairment Battery (SIB). Aging Clinical and Experimental Research, 1999, 11, 221-226.	2.9	10
290	Antioxidant Agents in Alzheimers Disease. Central Nervous System Agents in Medicinal Chemistry, 2008, 8, 48-63.	1.1	10
291	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	2.6	10
292	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	2.6	10
293	Telomeres Increasingly Develop Aberrant Structures in Aging Humans. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 230-235.	3.6	10
294	Comparative kinetics of oxiracetam in serum and CSF of patients with dementia of Alzheimer type. European Journal of Drug Metabolism and Pharmacokinetics, 1990, 15, 75-78.	1.6	9
295	Physical activity and cardiovascular health in the elderly. Aging Clinical and Experimental Research, 1998, 10, 13-25.	2.9	9
296	Area-Specific Differences in OH8dG and mtDNA4977 Levels in Alzheimer Disease Patients and Aged Controls. Rejuvenation Research, 1999, 2, 209-216.	0.2	9
297	PLASMA LIPID PEROXIDATION AND VITAMIN C STATUS IN HEALTHY CENTENARIANS. Journal of the American Geriatrics Society, 1999, 47, 1038-1039.	2.6	9
298	Zinc, Metallothioneins, Longevity: Effect of Zinc Supplementation on Antioxidant Response: A Zincage Study. Rejuvenation Research, 2008, 11, 419-423.	1.8	9
299	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
300	cCOG: A webâ€based cognitive test tool for detecting neurodegenerative disorders. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12083.	2.4	9
301	Evaluating 2-[18F]FDG-PET in differential diagnosis of dementia using a data-driven decision model. NeuroImage: Clinical, 2020, 27, 102267.	2.7	9
302	Classification Models for Alzheimer's Disease Detection. Communications in Computer and Information Science, 2013, , 193-202.	0.5	9
303	INCREASED OXIDATIVE DAMAGE IN LYMPHOCYTES OF ALZHEIMER'S DISEASE PATIENTS. Journal of the American Geriatrics Society, 1997, 45, 1536-1537.	2.6	8
304	Dementia, depression and parkinsonism: A frequent association in the elderly. Journal of Alzheimer's Disease, 2001, 3, 553-562.	2.6	8
305	Effects of vitamin A administration on serum thyrotropin concentrations in healthy human subjects. Metabolism: Clinical and Experimental, 2002, 51, 691-694.	3.4	8
306	Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Molecular Psychiatry, 2013, 18, 739-739.	7.9	8

#	Article	IF	CITATIONS
307	Fatigue as a clinical sign of biological aging: exploratory analyses from the <scp>MINDED</scp> project. Geriatrics and Gerontology International, 2016, 16, 533-534.	1.5	8
308	Impact of the earthquake of September 26, 1997 in Umbria, Italy on the socioenvironmental and psychophysical conditions of an elderly population. Aging Clinical and Experimental Research, 2000, 12, 281-286.	2.9	7
309	CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 446-458.	1.3	7
310	Italian version and normative data of Addenbrooke's Cognitive Examination III. International Psychogeriatrics, 2019, 31, 241-249.	1.0	7
311	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
312	Medico-legal assessment of personal damage in older people: report from a multidisciplinary consensus conference. International Journal of Legal Medicine, 2020, 134, 2319-2334.	2.2	7
313	Neuroendocrine markers in aging brain: Clinical and neurobiological significance of dexamethasone suppression test. Aging Clinical and Experimental Research, 1990, 2, 173-179.	2.9	6
314	Superficial Siderosis of the Central Nervous System: A 70-Year-Old Man with Ataxia, Depression and Visual Deficits. Gerontology, 2001, 47, 93-95.	2.8	6
315	User experience and acceptance of a device assisting persons with dementia in daily life: a multicenter field study. Aging Clinical and Experimental Research, 2022, 34, 869-879.	2.9	6
316	Lack of Energy and Negative Health-Related Outcomes in Nursing Home Residents: Results From the INCUR Study. Journal of the American Medical Directors Association, 2016, 17, 525-529.	2.5	5
317	Hyperhomocysteinemia and Oxidative Stress in Ischemic Stroke. Stroke, 2001, 32, 275-278.	2.0	4
318	Validation study of the Italian version of Communication Activities of the Daily Living (CADL 2) as an ecologic cognitive assessment measure in older subjects. Neurological Sciences, 2019, 40, 2081-2088.	1.9	4
319	Lower serum levels of IL-13 is associated with increased carotid intima-media thickness in old age subjects. Aging Clinical and Experimental Research, 2020, 32, 1289-1294.	2.9	4
320	Effect of Acetyl- <i>L</i> -Carnitine on Serum Levels of Cortisol and Adrenocorticotropic Hormone and Its Clinical Effect in Patients with Senile Dementia of Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1990, 1, 165-168.	1.5	3
321	Oxidative stress and lymphocytes in Alzheimer disease. Archives of Gerontology and Geriatrics, 1998, 26, 313-316.	3.0	3
322	The Multifaceted Aspects of Alzheimer's Disease: From Social to Molecular Problems. Journal of Alzheimer's Disease, 2007, 12, 1-1.	2.6	3
323	Fetal variant of circle of the Willis and bilateral symmetrical parietal stroke. Neurological Sciences, 2012, 33, 309-311.	1.9	3
324	Telomerase activation and human health-span: an open issue. Aging Clinical and Experimental Research, 2018, 30, 221-223.	2.9	3

#	Article	IF	CITATIONS
325	The Effects of Aging and Endurance Exercise on Cardiovascular Performance in Healthy Elderly: A Review of the Literature. The American Journal of Geriatric Cardiology, 1998, 7, 25-32.	0.6	3
326	Blood pressure and functional aspects of the aging brain. Archives of Gerontology and Geriatrics, 1989, 9, 155-161.	3.0	2
327	Low Levels of 4977 BP-deleted Molecules of Mitochondrial DNA in the Presence of High OH8DG Contents in Healthy Subjects and Alzheimer's Disease Patients. Annals of the New York Academy of Sciences, 1998, 854, 494-494.	3.8	2
328	Oxidative stress in Alzheimer's disease: a selective status report. Neuroscience Research Communications, 2004, 35, 202-212.	0.2	2
329	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2
330	Subjective memory complaints and depression as clinical symptoms of disseminated nocardiosis by <i>Nocardia abscessus </i> . Geriatrics and Gerontology International, 2016, 16, 1167-1168.	1.5	2
331	[P1–375]: DATAâ€ÐRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. Alzheimer's and Dementia, 2017, 13, P405.	0.8	2
332	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , .		2
333	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	2.2	2
334	The "Artwork Effect―paradigm: A model for planning and assessing cognitive stimulation for people with dementia through museum visits. Dementia, 2020, 19, 2867-2875.	2.0	2
335	Antioxidant Clinical Trials in Mild Cognitive Impairment and Alzheimer's Disease. Oxidative Stress in Applied Basic Research and Clinical Practice, 2013, , 223-232.	0.4	2
336	Cognitive Decline. Practical Issues in Geriatrics, 2018, , 67-80.	0.8	2
337	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
338	Al-Based Predictive Modelling of the Onset and Progression of Dementia. Smart Cities, 2022, 5, 700-714.	9.4	2
339	P4-235 Protein oxidation, lipid peroxidation and antioxidant status are similarly altered in Alzheimer disease and vascular dementia. Neurobiology of Aging, 2004, 25, S542.	3.1	1
340	P1-019 Behavioral and psychological symptoms in dementia: a population-based study. Neurobiology of Aging, 2004, 25, S99.	3.1	1
341	Introduction. Disease-a-Month, 2010, 56, 105.	1.1	1
342	Effect of Mediterranean Diet on Healthy Brain Aging. , 2018, , 89-101.		1

#	Article	IF	Citations
343	DPP-4 inhibitors: meeting the needs of the very old population. Acta Diabetologica, 2019, 56, 819-819.	2.5	1
344	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.8	1
345	Cholinesterase inhibitors in dementias. , 2020, , 457-475.		1
346	Usability testing of the first prototype of the MementoÂsystem: a technological device to promote an independent living in people with dementia. Disability and Rehabilitation: Assistive Technology, 2022, , 1-10.	2.2	1
347	Clinical physiology-pharmacology: Age-disease-drug-related hypernatremia and hyperphosphatemia. Geriatric Nephrology and Urology, 1995, 5, 177-179.	0.3	0
348	Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes from Normal Aged People and Alzheimer's Disease Patients., 0,, 363-369.		0
349	The brain of the elderly between normality and pathology: Techniques and technologies for the evaluation. Archives of Gerontology and Geriatrics, 2001, 33, 77-80.	3.0	O
350	MEMORY ABILITIES IN HEALTHY ELDERLY SUBJECTS: A FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY. , 2002, , .		0
351	P3-114 Comorbidity and polipharmacotherapy in dementia: the regal project in Italy. Neurobiology of Aging, 2004, 25, S387.	3.1	O
352	O1-06-01 Cognitive impairment is the major risk factor of adverse events in hospitalised elderly patients. Neurobiology of Aging, 2004, 25, S21.	3.1	0
353	P2-175 Role of proton magnetic resonance spectroscopy (1H-MRS) in predicting the conversion of mild cognitive impairment to dementia. Neurobiology of Aging, 2004, 25, S276-S277.	3.1	O
354	"Oldest old―man with odynophagia and generalized asthenia: It could be tetanus!. Geriatrics and Gerontology International, 2016, 16, 885-887.	1.5	0
355	[P1–009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P234.	:o.8	O
356	[P1â€"326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.8	0
357	[O4–03–06]: SHORTâ€₹ERM RESPONSE IS NOT PREDICTIVE OF LONGâ€₹ERM RESPONSE TO ACETYLCHOLINESTERASE INHIBITORS IN OLD AGE SUBJECTS WITH ALZHEIMER's DISEASE: A †REAL WORLD' STUDY. Alzheimer's and Dementia, 2017, 13, P1234.	⁴ 0.8	O
358	P1â€328: CONSISTENCY OF MUISTIKKO WEBâ€BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME. Alzheimer's and Dementia, 2018, 14, P418.	0.8	0
359	P2â€350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. Alzheimer's and Dementia, 2018, 14, P821.	0.8	O
360	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, P820.	0.8	0

#	Article	IF	CITATIONS
361	Telomere Targeting. , 2018, , .		O
362	Differential diagnosis of dementia combining webâ€based cognitive testing and MRI. Alzheimer's and Dementia, 2020, 16, e042626.	0.8	0
363	Plasmaâ€based biomarkers for Aβ and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046490.	0.8	O
364	Advanced Research in Telomeres and Disease Risk. , 2017, , 149-161.		0
365	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2020, , 1-9.		0
366	Editorial for the Special Issue "Molecular Bases of Senescence― International Journal of Molecular Sciences, 2021, 22, 11873.	4.1	0
367	Prevention of Age-Related Cognitive Impairment, Alzheimer's Disease, and Dementia. , 2021, , 3948-3956.		0
368	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. Alzheimer's and Dementia, 2021, 17, .	0.8	0